Hong Kong Renewable Energy Stock News

Haidilao International Holding Ltd. recently completed a major leadership reshuffle, with long-time chairman Zhang Yong assuming the chief executive officer role and four younger executives promoted to the board, while several existing executive directors, including the former CEO, resigned. This overhaul signals an emphasis on grooming internally trained, operations-focused leaders drawn from regional management and product development roles, potentially influencing how the group executes...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Alibaba Health Information Technology Limited ( HKG:241 ) shareholders would be excited to see that the share price has...

Key Insights Planetree International Development's significant insider ownership suggests inherent interests in...

ASMPT Limited ( HKG:522 ) shares have had a really impressive month, gaining 25% after a shaky period beforehand...

To find a multi-bagger stock, what are the underlying trends we should look for in a business? In a perfect world, we'd...

Zhong Jia Guo Xin Holdings Company Limited ( HKG:899 ) shareholders (or potential shareholders) will be happy to see...

As Asian markets continue to navigate a landscape marked by geopolitical tensions and economic shifts, investors are increasingly exploring diverse opportunities across the region. Penny stocks, often seen as smaller or newer companies with potential for growth, remain an intriguing segment for those seeking untapped value. In this article, we explore three Asian penny stocks that stand out for their financial strength and potential to offer compelling investment opportunities in today's...

LifeTech Scientific (SEHK:1302) is back in focus after two recent China NMPA decisions related to its vascular stent graft pipeline, raising fresh questions about how investors should think about the company’s product portfolio and valuation. See our latest analysis for LifeTech Scientific. Those two NMPA decisions have arrived during a period of renewed interest in the stock, with a 1 day share price return of 4.88%, a 7 day return of 9.55% and a 30 day return of 12.42%. However, the 90 day...

China Jinmao Holdings Group (SEHK:817) has released unaudited contracted sales figures for December and for the full year 2025, giving investors a fresh data point on project sales momentum and capital deployment. See our latest analysis for China Jinmao Holdings Group. The new contracted sales update lands after a mixed year for the stock, with a 1 month share price return of 6.56% and a 1 year total shareholder return of 50.53%. However, the 3 year and 5 year total shareholder returns...

Luye Pharma Group (SEHK:2186) is in focus after Chinese regulators accepted a New Drug Application for a new Ruoxinlin indication targeting Generalized Anxiety Disorder, supported by Phase III data in a large patient population. See our latest analysis for Luye Pharma Group. The NDA news has arrived after a mixed period for Luye Pharma Group. The 30 day share price return is 5.99%, while the 90 day share price return shows a 16.16% decline. The 1 year total shareholder return of 49.75%...

SJM Holdings Limited recently completed a cash tender offer for its 4.500% senior notes due 2026, accepting US$170,115,000 in principal and paying accrued interest of US$21.125 per US$1,000, leaving US$329,885,000 of these notes outstanding. This sizeable retirement of near-term debt highlights active balance sheet management that could influence how investors view SJM Holdings’ financial flexibility and risk profile. Against this backdrop, we will explore how SJM Holdings’ active debt...

Chongqing Rural Commercial Bank (SEHK:3618) is back in focus after the formal appointment of Mr. Liu Xiaojun as chairman and executive director, a leadership change that could reshape governance priorities and influence how investors view the stock. See our latest analysis for Chongqing Rural Commercial Bank. The leadership change comes as Chongqing Rural Commercial Bank’s HK$6.0 share price has faced pressure in recent months, with a 90 day share price return of a 9.09% decline contrasting...

China Power International Development Limited recently appointed Mr. GUI Xude as Executive Director and Chairman of the Board, succeeding Mr. WANG Zichao, while also releasing unaudited figures showing higher monthly but slightly lower year‑to‑date electricity sales through November 2025. An interesting aspect of this transition is that Mr. GUI simultaneously assumes leadership of key risk, strategy and sustainability committees, potentially influencing how the company balances growth,...

In early January 2026, Cirrus Aircraft announced its 2026 SR Series G7+ models for the SR20, SR22 and SR22T, adding upgraded avionics, expanded global connectivity, new propeller options and refreshed designs across its best-selling single-engine piston lineup. A particularly distinctive element of the launch is Cirrus Global Connect’s expanded always-on weather and communication capabilities, which deepen integration between cockpit technology and continuous global connectivity for pilots...

First Pacific Company Limited has already completed a substantial stock split or significant stock dividend, with a ratio of 1 to 86.95652, effective 16 December 2025. This unusually large split reshapes the company’s share count and trading dynamics, which can influence how investors assess liquidity and accessibility. Next, we’ll examine how this very large stock split interacts with First Pacific’s existing investment narrative around capital management and growth. Rare earth metals are...

In January 2026, Dispatch Bio and CARsgen Therapeutics announced a clinical collaboration in China to start a Phase 1 trial evaluating DISP-11, which combines Dispatch’s Flare platform and DV-10 virus with CARsgen’s approved BCMA-targeting CAR T therapy zevor-cel in patients with epithelial solid tumors. This alliance is significant because it seeks to adapt a multiple myeloma CAR T-cell therapy for solid tumors, an area where immunotherapies have historically faced major biological...

InSilico Medicine Cayman TopCo (SEHK:3696) has drawn attention after a sharp 43.09% move over the past week, prompting investors to reassess how its AI driven drug discovery model lines up with its current valuation. See our latest analysis for InSilico Medicine Cayman TopCo. The recent 7 day share price return of 43.09%, on top of a year to date share price return of 54.20% and a latest close of HK$57.95, points to momentum building around InSilico Medicine Cayman TopCo as investors reassess...

Lenovo Group (SEHK:992) has become a talking point after a busy CES 2026 and Tech World, where it showcased personal AI agents across devices, AI focused PCs and phones, and enterprise grade AI platforms. See our latest analysis for Lenovo Group. Despite the busy run of AI and product launches, Lenovo’s HK$9.0 share price has a 30 day share price return of 5.86% decline and a 90 day share price return of 21.81% decline, while the 3 year total shareholder return of 67.77% points to stronger...

China Nonferrous Mining Corporation Limited has resumed full production at Zambia’s Chambishi Southeast Mine from 1 January 2026 after completing shaft rehabilitation, and has issued 2026 guidance targeting approximately 484,000 tonnes of copper alongside sizeable sulphuric acid, liquid sulphur dioxide and cobalt output. An interesting aspect of this update is that overall copper output is guided to remain substantial even as blister and anode volumes ease during planned smelter maintenance...

December sales update and why it matters for shareholders Country Garden Holdings (SEHK:2007) has released preliminary unaudited sales figures for December 2025, reporting contracted sales attributable to shareholders of about RMB 2.69b and contracted sales gross floor area of roughly 0.31 million square meters. For investors tracking this China focused developer, these monthly numbers provide another reference point alongside the company’s recent share price performance, multi year total...

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...

Sino Biopharmaceutical’s board previously reported enrollment of the first patient in a global first Phase III trial of TDI01, a highly selective ROCK2 inhibitor for idiopathic pulmonary fibrosis, following encouraging Phase II efficacy and safety data. The same molecule has also entered Breakthrough Therapy Designation review in China for chronic graft-versus-host disease, underlining its potential relevance across multiple serious immune-related conditions. We’ll now examine how advancing...

Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...